Novartis Q1 2026 Results: Strong Growth in Priority Brands Amid Generic Erosion
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Tag: 2026
Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Abbott Announces Q1 2026 Results Amidst Strategic Abbott Acquisition of Exact Sciences
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
Johnson & Johnson Q1 2026 Results: Financial Growth and Pipeline Breakthroughs
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
